Bayer Benefits From Diversification, Despite Flat Pharma Growth in 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm's ability to pursue smaller acquisitions or partnerships is improving because of a reduction in net debt.
You may also be interested in...
Diversification, Not Genzyme, Is The Theme Of Sanofi's Year-End Financial Report
Sanofi's sales declined by 1% in 2010 and net income increased by 2.6%, although €2 billion in sales were lost to generics during the year.
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions
Bayer Purchase Of Schering AG Would Give Firm Focus On Specialty Pharma
$19. 5 bil. offer by Bayer will likely thwart hostile takeover of Schering by Merck KgaA.